Conference Day One

8:30 am Coffee & Check In

9:20 am Chair’s Opening Remarks

  • Brett Miller Head of Isotope Manufacturing & Supply, Novartis AG

From Scarcity to Stability: Securing Supply Chain Pipelines for the Future of Radiotherapies

9:30 am Panel Discussion: Addressing Barriers in Supply Chains to Ensure Reliable Isotope Access & Consistent Patient Delivery

Synopsis

  • Identify sourcing and logistics bottlenecks including cold chain constraints, regulatory delays, and cross-border customs challenges that impact isotope availability and the timely delivery of radiopharmaceuticals.
  • Compare centralized and local production models for short- and long-lived isotopes to minimize supply chain risks, costs, and lead times while ensuring the delivery of therapies to clinical sites on time.
  • Assess the impact of sourcing disruptions, like lost shipments or transport delays, on radio decay, and manufacturing timelines, and explore strategies to maintain dose integrity and minimize patient treatment disruptions.
  • Integrate supply chain planning and tracking strategies to optimize clinical demand fulfilment.

10:30 am Morning Break & Networking

Enhancing Radiotherapy Production Capacity Through Technological Innovation, Infrastructure Optimization & Logistical Advancements

11:30 am Harnessing Automation & Digitization in Targeted Radiotherapy Manufacturing to Ensure Consistent Quality

Synopsis

  • Consider high-impact areas for automation to improve batch consistency, reduce human error, and enhance operator safety.
  • Discuss integration challenges in retrofitting automation into facilities while maintaining GMP compliance.
  • Evaluate the return on investment, the benefits and the challenges of automation, including improved scalability and consistency versus difficulties like maintenance requirements.
  • Assess the use of AI platforms in automation of manufacturing processes.

12:00 pm Roundtable Discussion: Addressing Facility Downtime & Regulatory Delays by Designing Robust Infrastructure Strategy to Accelerate Safe, Scalable Radiopharmaceutical Manufacturing

Synopsis

  • Compare the cost, speed, and scalability trade-offs between building new facilities and repurposing existing infrastructure for radiopharmaceutical production.
  • Explore how isotope-specific properties (e.g. half-life, emission type, regulatory perception) impact facility design, contamination protocols, and downtime risk.
  • Understand how evolving regulatory expectations and environmental monitoring requirements influence long-term compliance, capacity, and facility utilization.

12:30 pm Lunch & Networking

Strategic Formulation Approaches for Maximizing Isotope-Specific Performance & Supply Efficiency

1:30 pm Translating Supply Chain Lessons from Long-Lived to Short-Lived Radiotherapeutics: Overcoming Gaps in Handling, Quality & Distribution

Synopsis

  • Explore how established distribution models for isotopes such as Lutetium-177 differ from those required for short half-life radiotherapies (Lead-212 and Astatine-211), and what adaptations are needed.
  • Discuss what elements of long-lived isotope supply (licensing, training, automation, and packaging) can be reused, and where entirely new systems are needed for short-lived compounds.
  • Examine approaches to minimize dose loss due to delays, weather, or site readiness when working with short half-life products, including localized production vs hub-and-spoke delivery.

2:00 pm Maximizing Radiopharmaceutical Production Speed with Best-in-Class Precursor Selection

Synopsis

  • Discuss how to boost reliability and yield through consistent, GMP-grade materials that minimize batch failures and waste.
  • Streamline downstream processing by reducing purification complexity with cleaner, high-purity reactions.
  • Reduce synthesis time by using precursors engineered for fast, efficient radiolabeling under mild conditions.

2:30 pm Afternoon Break & Poster Session

Accelerating Clinical Submissions by Clarifying Regulatory Expectations & Filing Scope Across Radiopharmaceutical Development

3:30 pm Panel Discussion: Discussing Perspectives on Regulatory Expectations to Improve Submission Clarity & Accelerate Development Timelines

Synopsis

  • Explore key differences in manufacturing practices for pharmaceutical vs industrial isotope use, including how processes, quality standards, and documentation are adapted for GMP compliance.
  • Review common regulatory questions and challenges faced when submitting Drug Manufacturing Files (DMFs), and how these vary across agencies like the FDA and EMA.
  • Discuss how to balance confidentiality with regulatory transparency, and how pharma and isotope suppliers can better align to meet submission requirements without disclosing sensitive IP.

4:30 pm Navigating Filing Scope for Targeted Radiotherapies & Engaging Authorities Under Evolving Guidance Standards to Fast-Track Submissions

Synopsis

  • Clarify how to define the appropriate Module 3 scope when filing radiopharmaceuticals with multiple radionuclides, production routes, or variable target materials.
  • Explore how to establish target purity profiles and target product profiles, and how these impact quality specifications, comparability, and filing complexity.
  • Discuss best practices for early engagement with regulators (FDA, EMA, etc.) to align on isotope source qualification, dossier structure, and evolving quality standards.

5:00 pm Chair’s Closing Remarks

  • Brett Miller Head of Isotope Manufacturing & Supply, Novartis AG

5:05 pm End of Conference Day One